Cybin Inc., a clinical-stage biopharmaceutical company, has filed an amended report with the SEC for June 2024, correcting an inadvertent incorporation by reference in its original Form 6-K and updating the date of a news release in the Exhibit Index. The company, which focuses on developing psychedelic-based treatments for mental health disorders, reported significant progress in its fiscal year 2024. Cybin received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for Major Depressive Disorder, and completed site selection for a Phase 3 multinational study expected to begin in summer 2024. Cybin also initiated a Phase 2 study for CYB004, targeting Generalized Anxiety Disorder. Financially, Cybin reported a cash total of C$209 million as of March 31, 2024, and closed an oversubscribed private placement of U.S.$150 million. Despite these advancements, the company experienced an increased net loss of C$78 million for the year, compared to C$47 million the previous year. The company's CEO, Doug Drysdale, expressed optimism about the upcoming Phase 3 study and the potential impact of their treatments on mental health disorders.

Cybin Inc., a clinical-stage biopharmaceutical company, has filed an amended report with the SEC for June 2024, correcting an inadvertent incorporation by reference in its original Form 6-K and updating the date of a news release in the Exhibit Index. The company, which focuses on developing psychedelic-based treatments for mental health disorders, reported significant progress in its fiscal year 2024. Cybin received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for Major Depressive Disorder, and completed site selection for a Phase 3 multinational study expected to begin in summer 2024. Cybin also initiated a Phase 2 study for CYB004, targeting Generalized Anxiety Disorder. Financially, Cybin reported a cash total of C$209 million as of March 31, 2024, and closed an oversubscribed private placement of U.S.$150 million. Despite these advancements, the company experienced an increased net loss of C$78 million for the year, compared to C$47 million the previous year. The company's CEO, Doug Drysdale, expressed optimism about the upcoming Phase 3 study and the potential impact of their treatments on mental health disorders.